Answers are grounded in this paper and cite their sources.
The development of recombinant interleukin-2 (rIL-2) as a treatment for cancer represented an important milestone in the development of biologic therapies. IL-2 is a natural modulator of the immune system that stimulates specialised immune system cells, namely cytotoxic T-lymphocytes (CTLs) and natural killer cells (NKCs). These cells could potentially recognise and destroy tumour cells throughout the body. However, the exact mechanism(s) by which IL-2 mediates a tumouricidal effect is not well known. Recombinant IL-2 has been primarily used in the treatment of advanced renal cell cancer (RCC) and malignant melanoma (MM). Nevertheless, the benefit of rIL-2 therapy remains very modest in these conditions. Initial results demonstrated objective response rates (shrinkage of tumour volume to less than 50%) in the 15 - 20% range with some durable responses. However, the overall response rates were lower than originally hoped for with this therapy. Moreover, the use of rIL-2 may be associated with significant side effects that could be life threatening. Despite numerous studies with rIL-2, the optimal dose and treatment schedules remain a controversial topic. To date, there are no clear immunological parameters able to predict biological response to rIL-2 administration to achieve maximum therapeutic index. In addition, combination therapy with either immunomodulators or cytotoxic drugs, is being very actively investigated.
No takes yet. Share an insight, caveat, or question.
Gurjal et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: